Equity Overview
Price & Market Data
Price: $18.21
Daily Change: -$0.09 / 0.49%
Range: $17.46 - $18.70
Market Cap: $892,370,048
Volume: 123,051
Performance Metrics
1 Week: 10.16%
1 Month: -11.52%
3 Months: -16.70%
6 Months: -37.16%
1 Year: 4.84%
YTD: -19.07%
Company Details
Employees: 62
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.